BLS Pharmaceuticals Limited (ASX:BLS)

Market Cap	268.30M +208.8%
Revenue (ttm)	73.91M +152.4%
Net Income	15.40M +214.1%
EPS	0.07 +191.3%
Shares Out	230.30M
PE Ratio	17.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141,336
Open	1.180
Previous Close	1.180
Day's Range	1.165 - 1.190
52-Week Range	0.330 - 1.210
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About BLS Pharmaceuticals

BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan. The company offers medical cannabis, MDMA, psilocybin, prescription medicines, probiotics, NADs, and consumer health products under the Dr Watson and PCC brands. It also provides pharmaceutical manufacturing, wholesale, distribution, import, export, and contract drug manufacturing services for investigational and psychotropic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BLS

Financial Performance

In fiscal year 2026, BLS Pharmaceuticals's revenue was 73.91 million, an increase of 152.42% compared to the previous year's 29.28 million. Earnings were 15.40 million, an increase of 214.15%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 14, 2026

Data Sources Report a data error